Research Laboratory Inaugurated in Catania
Zug, Catania (ots)
- AmVac AG, a Swiss biopharmaceutical company
based in Zug, is starting its first research cooperation program with
Bayer Innovation GmbH on the development of a new influenza vaccine.
Joint research and development work is beginning with the Bayer
subsidiary Icon Genetics GmbH on a novel production approach.
Antigens are to be produced for the first time in tobacco plants
which along with AmVac AG's adjuvant MALP-2 are to be developed into
an efficient new generation of flu vaccines. The research unit for
the preclinical work is being opened today at the Parco Scientifico e
Tecnologico in Catania, Sicily.
By switching the production base to plants, the magICON technology
patented by Icon Genetics enables shorter expression times compared
with current methods. As there is no contamination by animal proteins
such as egg protein, the safety profile for producing antigens in
tobacco plants is outstanding and has no allergy risks. It also has
the potential to reduce production costs thanks to the high yields
obtained in cultivating antigens. By using the innovative and
high-potential adjuvant MALP-2, AmVac AG can make a decisive
contribution to developing a new influenza vaccine. The immune system
is stimulated, thus significantly increasing the efficacy of a
vaccination. At the same time, it should be possible to reduce the
amount of the antigen used and, therefore, to produce large
quantities of vaccine more quickly and cost-efficiently.
Melinda-Kinga Karpati, CEO of AmVac AG, explains, "We anticipate
that this collaboration with Bayer's Icon Genetics will bring us
rapid results for the joint project and for our Malp-2 adjuvant. We
are carrying out the work in Catania because here we have both good
scientists and a high level of political support for our research.
Here in Catania, we have found ideal conditions for our project with
AmVac. Our goal is to achieve preclinical results with our highly
motivated team locally as soon as possible and to prepare effectively
for any clinical trials."
About AmVac AG
AmVac AG is a biopharmaceutical company based in Switzerland. The
company focuses on the vaccine market which is displaying
above-average growth rates. Its pipeline includes two close-to-market
therapeutic vaccines in the fields of gynecology and urology. Other
innovative vaccines and technologies are under development. The
well-known market research company Frost & Sullivan presented its
sought-after Enabling Technology of the Year Award to AmVac AG in
ots Originaltext: AmVac AG
Head of PR/IR